Mental Process
Bayer Acquires European Rights to BridgeBio’s Acoramidis for ATTR-CM Therapy
Bayer, BridgeBio Pharma, Acoramidis, ATTR-CM, Exclusive License, European Rights, Royalties, Milestone Payments, Phase 3 Data, Potential Approval, Low-Thirties Percent Royalties, EMA Approval 2025, PDUFA Action Date November 2024, Vyndaqel Rival, Blockbuster Potential, Cardiovascular Infrastructure, Investor Hopes for Clarity on Split Strategy.
Sarepta’s ELEVIDYS Gaining Ground Amidst Anticipation for Expanded Label Approval
ELEVIDYS, Age, Muscular Dystrophy, Duchenne, Sarepta, Labels (device), Child
Headlight: PillPack Co-Founder Backs Mental Health Startup’s $18M Funding in Transformative Care Mission
PillPack, Amazona, Clinician, Practice Experience
Sanofi guarantees employees one year of salary and support after cancer diagnosis
Workers, Malignant Neoplasms, sanofi, Affecting, Cancer Diagnosis